Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

at the company’s upcoming R&D day on June 20, 2007 at 2 pm (CET) and provide then further details about preclinical and clinical results.


About the combined phase I/IIa study

The multi-centre, randomized, placebo-controlled and double-blind study included 48 male and female patients suffering from moderate to severe plaque psoriasis. An initial part of the study with a total of 24 participants evaluated the safety and tolerability of ascending doses of the vaccine (100 ?g, 300 ?g). It was followed by a second study part with a total of 24 participants that was designed to evaluate exploratory efficacy of the highest previously tested vaccine dose (i.e. 300 ?g) compared to placebo. Patients of this latter group were randomized 1:1 into the vaccine-treated and the placebo group and either received 5 subcutaneous injections of 300 ?g CYT007-TNFQb or placebo at weeks 0, 2, 4, 8 and 12. Upon entry into the study and then every two weeks up to week 16, the patients’ disease severity was determined by the Psoriasis Area and Severity Index (PASI).

About psoriasis and CYT007-TNFQb

Psoriasis is a common chronic skin disorder that affects 1-3% of the world’s population (National Psoriasis Foundation, USA). Plaque psoriasis is the most common form of the disease (>80% of cases) and it is characterized by inflamed red patches of skin topped with silvery white scales. While there are a number of medications that may help to control the symptoms of psoriasis, there is as yet no cure. Psoriasis is considered to be linked to an overactive immune system where inflammatory cytokines play an essential role. The inflammatory cytokine tumor necrosis factor alpha (TNF-?) has been described as a key molecule in the pathogenesis of psoriasis. Consequently, recently approved anti-TNF-? biologics have proven effective; however, they have to be administered frequently and at high doses and are therefore associated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... 25, 2014 Thousands of transvaginal mesh ... in a number of multidistrict litigations currently underway in ... Liebhard LLP reports. According to an Order issued on ... a Joint Status Conference in all of the proceedings ... been directed to submit a proposed agenda to the ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 AlignLife of ... unable to afford certain items. During the holiday season, AlignLife ... collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of ... staff such joy, knowing that we are able to give ... had it not been for the generosity of our patients." ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... News) -- Most head and neck cancer patients can ... treatment, but several factors may be associated with poor ... patients who were assessed nearly three years after they ... neck cancer. The U.S. researchers gave a speaking ...
... to develop genital cancer, especially as they grow older. ... sexes suffer from the condition, which is extremely difficult to ... of the similarity of the disease to human genital cancer ... Several human genital cancers, including cervical tumours, are known ...
... Nasal congestion can be a sign of severe asthma, ... when it comes to nasal complaints. Furthermore, more severe ... reveals a study from the Sahlgrenska Academy,s Krefting Research ... Respiratory Research , the population study included 30,000 randomly ...
... the effects of monensin emerged in a project investigating ... the growth of prostate cancer cells. The project involved ... found that small amounts of compounds disulfiram (Antabus), ... growth of prostate cancer cells without significant effects on ...
... The hectic pace of the holiday season can make it ... conditions to maintain normal routines and medication schedules. This can ... errors, according to the American Pain Foundation. But a ... over the holidays, the foundation says. If you,re traveling, ...
Cached Medicine News:Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2Health News:A possible cause -- and cure -- for genital cancer in horses? 2Health News:Nasal congestion can mean severe asthma 2Health News:Finnish researchers find a compound that prevents the growth of prostate cancer cells 2Health News:Hectic Holiday Pace Can Upset Medication Schedule 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: